6533b834fe1ef96bd129cb78

RESEARCH PRODUCT

Molecular Biology of Atherosclerotic Ischemic Strokes

Maria Chiara VelardoAntonino TuttolomondoMaria Grazia PuleoAntonio PintoFrancesca CorporaMario Daidone

subject

0301 basic medicineInflammasomesCerebral arteriesmicrogliaDiseaseReviewneuroinflammationBrain ischemialcsh:Chemistry0302 clinical medicineatherosclerosiStrokelcsh:QH301-705.5SpectroscopymicroRNAGeneral MedicineMKEYDKK-3Computer Science ApplicationsmicroRNAsBlood-Brain BarrierCardiologymedicine.symptomDectin-1medicine.medical_specialtyIschemiaBrain damageCatalysisInorganic Chemistry03 medical and health sciencesInternal medicineDiabetes mellitusmedicineischemic strokeAnimalsHumansPhysical and Theoretical ChemistryMolecular Biologybusiness.industryOrganic ChemistryAFmedicine.diseaseImmunity InnateNLRP3 inflammasome030104 developmental biologylcsh:Biology (General)lcsh:QD1-999atherosclerosisbusinessBBB030217 neurology & neurosurgeryDyslipidemiaCD200-CD200R

description

Among the causes of global death and disability, ischemic stroke (also known as cerebral ischemia) plays a pivotal role, by determining the highest number of worldwide mortality, behind cardiomyopathies, affecting 30 million people. The etiopathogenetic burden of a cerebrovascular accident could be brain ischemia (~80%) or intracranial hemorrhage (~20%). The most common site when ischemia occurs is the one is perfused by middle cerebral arteries. Worse prognosis and disablement consequent to brain damage occur in elderly patients or affected by neurological impairment, hypertension, dyslipidemia, and diabetes. Since, in the coming years, estimates predict an exponential increase of people who have diabetes, the disease mentioned above constitutes together with stroke a severe social and economic burden. In diabetic patients after an ischemic stroke, an exorbitant activation of inflammatory molecular pathways and ongoing inflammation is responsible for more severe brain injury and impairment, promoting the advancement of ischemic stroke and diabetes. Considering that the ominous prognosis of ischemic brain damage could by partially clarified by way of already known risk factors the auspice would be modifying poor outcome in the post-stroke phase detecting novel biomolecules associated with poor prognosis and targeting them for revolutionary therapeutic strategies.

10.3390/ijms21249372http://hdl.handle.net/10447/479767